Efficacy and Safety of MEDI3506 in Adult Subjects with Atopic Dermatitis

Study identifier:D9182C00001

ClinicalTrials.gov identifier:NCT04212169

EudraCT identifier:2019-003304-12

CTIS identifier:N/A

Study Complete

Official Title

A Phase 2 Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI3506 in Adult Subjects with Moderate-to-severe Atopic Dermatitis

Medical condition

Atopic Dermatitis

Phase

Phase 2

Healthy volunteers

No

Study drug

MEDI3506, Placebo

Sex

All

Actual Enrollment

148

Study type

Interventional

Age

18 Years - 65 Years

Date

Study Start Date: 09 Dec 2019
Primary Completion Date: 21 Jul 2022
Study Completion Date: 20 Sept 2022

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Aug 2023 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria